California State Teachers Retirement System reduced its position in Celldex Therapeutics Inc. (NASDAQ:CLDX) by 4.0% during the second quarter, Holdings Channel reports. The fund owned 200,400 shares of the biopharmaceutical company’s stock after selling 8,251 shares during the period. California State Teachers Retirement System owned approximately 0.20% of Celldex Therapeutics worth $880,000 as of its most recent SEC filing.
Several other institutional investors have also bought and sold shares of CLDX. State Street Corp raised its position in Celldex Therapeutics by 158.9% in the first quarter. State Street Corp now owns 8,561,225 shares of the biopharmaceutical company’s stock worth $32,362,000 after buying an additional 5,254,100 shares during the last quarter. A.R.T. Advisors LLC acquired a new position in Celldex Therapeutics during the first quarter worth approximately $3,446,000. Renaissance Technologies LLC acquired a new position in Celldex Therapeutics during the first quarter worth approximately $3,074,000. Norges Bank acquired a new position in Celldex Therapeutics during the fourth quarter worth approximately $9,378,000. Finally, RTW Investments LLC raised its position in Celldex Therapeutics by 58.2% in the first quarter. RTW Investments LLC now owns 989,376 shares of the biopharmaceutical company’s stock worth $3,740,000 after buying an additional 363,990 shares during the last quarter. Institutional investors and hedge funds own 78.41% of the company’s stock.
Celldex Therapeutics Inc. (NASDAQ:CLDX) traded down 4.76% during midday trading on Thursday, reaching $3.80. The company had a trading volume of 2,319,668 shares. The stock’s 50 day moving average price is $3.80 and its 200-day moving average price is $4.13. The firm’s market capitalization is $382.07 million. Celldex Therapeutics Inc. has a one year low of $2.96 and a one year high of $18.62.
Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.02. Celldex Therapeutics had a negative net margin of 2,383.60% and a negative return on equity of 47.59%. The company earned $1.39 million during the quarter, compared to the consensus estimate of $0.96 million. During the same period in the prior year, the business posted ($0.33) EPS. The company’s quarterly revenue was down 36.4% on a year-over-year basis. On average, equities research analysts anticipate that Celldex Therapeutics Inc. will post ($1.34) earnings per share for the current year.
CLDX has been the topic of a number of recent analyst reports. Jefferies Group lifted their price objective on Celldex Therapeutics to $5.00 and gave the stock a “hold” rating in a research note on Friday, August 5th. Cowen and Company reiterated an “outperform” rating and issued a $12.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday, June 7th. Finally, Wedbush reiterated a “neutral” rating and issued a $3.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday, August 9th. Six analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $10.75.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII).
Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics Inc. (NASDAQ:CLDX).
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.